Abstract: Provided is a method of manufacturing a positive electrode active material, which includes: (A) preparing a positive electrode active material precursor which includes a core portion including randomly aggregated primary particles and a shell portion surrounding the core portion and formed of primary particles oriented in a direction from a particle center to the outside and in which a ratio of a crystal grain size in the (100) plane to a crystal grain size in the (001) plane of the primary particles forming the shell portion is 3 or more; and (B) mixing the positive electrode active material precursor with a lithium-containing raw material and firing the mixture, wherein the lithium transition metal oxide has an average particle diameter (D50) that is 0.

Abstract: A rotating gas injection device for preventing damage to a rawinsonde balloon, comprising: a handgrip part; a gas injection tube; a ball bearing module including an inner ring, an outer ring, wherein the inner ring and the outer ring are rotatably engaged by means of the balls; and an outer ring cover positioned outside of the outer ring to form space between the outer ring cover and the outer ring; wherein, after an insertion of a neck of the rawinsonde balloon into the space, a distance between the outer ring and the outer ring cover is controlled to be decreased so that the neck of the rawinsonde balloon makes tight contact, and in response to an external force exerted on the neck of the rawinsonde, the outer ring is allowed to be rotated together with the neck by means of the balls.

Abstract: A rotating gas injection device for preventing damage to a rawinsonde balloon, comprising: a handgrip part; a gas injection tube; a ball bearing module including an inner ring, an outer ring, wherein the inner ring and the outer ring are rotatably engaged by means of the balls; and an outer ring cover positioned outside of the outer ring to form space between the outer ring cover and the outer ring; wherein, after an insertion of a neck of the rawinsonde balloon into the space, a distance between the outer ring and the outer ring cover is controlled to be decreased so that the neck of the rawinsonde balloon makes tight contact, and in response to an external force exerted on the neck of the rawinsonde, the outer ring is allowed to be rotated together with the neck by means of the balls.

Abstract: A cleaning method according to the present invention comprises mounting the metal filter on a jig that is vertically elevatable and horizontally slidable in a cleaning bath so that the opening is faced downward, descending the jig so that a first nozzle installed in the cleaning bath enters the opening, injecting a predetermined amount of water and a cleaning solution into the cleaning bath so that the metal filter is immersed, spraying compressed air through the first nozzle to discharge bubbles of the compressed air toward an inner surface of the metal filter, draining the cleaning bath, spraying water through a second nozzle to remove the cleaning solution from the metal filter, and spraying the compressed air through the first nozzle to dry the metal filter. An apparatus for cleaning a metal filter is also disclosed.

Abstract: The present invention relates to a method for predicting a drug-drug interaction and a drug-food interaction by using structural information of a drug and, more particularly, to a method for predicting the mechanism of action and activity of a drug interaction through interaction prediction results expressed by a standardized sentence. When using a method for predicting a drug interaction according to the present invention, a drug interaction can be predicted quickly and accurately, and in particular, activity information of an unknown compound can also be predicted by expressing a prediction result by means of a sentence, and thus the method is very useful for developing a drug exhibiting desired activity without causing adverse effects.

Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.

Abstract: A sustained release preparation of a human growth hormone conjugate is disclosed. The sustained release preparation contains a sustained release human growth hormone (hGH) conjugate resulting from conjugation between an immunoglobulin Fc region and a human growth hormone (hGH) as an active peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. A freeze dried preparation and a liquid preparation including the sustained release human growth hormone conjugate, a production method for the freeze dried preparation, a method of reconstituting the freeze dried preparation, and a kit containing the freeze dried preparation and a reconstituting solution are also disclosed.

Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.

Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.

Abstract: A positive electrode active material precursor having a uniform particle size distribution and represented by Formula 1, wherein a percentage of fine powder with an average particle diameter (D50) of 1 ?m or less is generated when the positive electrode active material precursor is rolled at 2.5 kgf/cm2 is less than 1%, and an aspect ratio is 0.93 or more, and a method of preparing the positive electrode active material precursor [NixCoyM1zM2w](OH)2??[Formula 1] in Formula 1, 0.5?x<1, 0<y?0.5, 0<z?0.5, and 0?w?0.1, M1 includes at least one selected from the group consisting of Mn and Al, and M2 includes at least one selected from the group consisting of Zr, B, W, Mo, Cr, Nb, Mg, Hf, Ta, La, Ti, Sr, Ba, Ce, F, P, S, and Y. A method of preparing the positive electrode active material precursor is also provided.

Abstract: A co-precipitation reactor with a continuous filtering system mounted, wherein the co-precipitation reactor includes a main body accommodating a reactant for reaction therein, an input unit inputting the reactant into the main body, and a filter unit installed in the main body to filter a precursor of the precursor generated by reacting with the reactant in the main body and a reaction solution.

Abstract: The present disclosure relates to a cucurbituril-polyethylenimine-silica complex, a method for preparing the same and a carbon dioxide absorbent containing the same. According to the present disclosure, a cucurbituril-polyethylenimine-silica complex may be prepared by forming a complex wherein a cucurbituril is bound to polyethylenimine and including the same inside silica, and it may be used as a carbon dioxide absorbent with superior thermal stability and prevented formation of urea.

Abstract: A co-precipitation reactor with a continuous filtering system mounted, wherein the co-precipitation reactor includes a main body accommodating a reactant for reaction therein, an input unit inputting the reactant into the main body, and a filter unit installed in the main body to filter a precursor of the precursor generated by reacting with the reactant in the main body and a reaction solution.

Abstract: Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.

Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.

Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.

Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

Abstract: A liquid formulation of highly concentrated long-acting human growth hormone conjugate contains a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent. A method for preparing the same is provided.

Abstract: An insulin analog has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin. A conjugate is prepared by linking the insulin analog and a carrier. A long-acting formulation includes the conjugate.

Abstract: The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same.